Ocular Therapeutix, Inc. (OCUL)

NASDAQ: OCUL · USD

$7.25

+0.52 (+7.8%)· Recorded snapshot

Market cap	1.6B
Revenue (ttm)	52.1M
Net income (ttm)	-301.4M
EPS (ttm)	-$1.41
Shares out	219.6M
Volume	2,317,456
Beta	0.99

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 52.1M
Net income (ttm): -301.4M
EPS (ttm): -$1.41
Market cap: 1.6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-73

P25 n/aP50 n/aP75 n/a

ROIC-39.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All OCUL indicators

Market & fundamental data

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001393434
Company name	Ocular Therapeutix, Inc.
Country	United States
Country code	US
CUSIP number	67576A100
Earnings date	2026-11-10
Earnings time	bmo
Employees	325
Employees change	51
Employees growth	18.61%
Enterprise value	$1.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2006
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2014-07-25
Is primary listing	Yes
Is SPAC	No
ISIN number	US67576A1007
Last 10-K release date	2026-02-05
Last earnings date	2026-08-03
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.6B
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$7.25
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	OCUL
U.S. state	Massachusetts
Website	https://www.ocutx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-19.52%
EV/Sales	20.23x
FCF / EV yield	-24.22%
FCF yield	-16.22%
Forward EV/Sales	18.47x
Forward P/S	27.57x
P/B ratio	2.84x
P/S ratio	30.21x
Price / tangible book value	3.02x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-603.03%
Pretax margin	-579.09%
Profit per employee	$-927,529
Revenue per employee	$160,169
ROA	-34.95%
ROA (5Y)	-25.86%
ROCE	-50.46%
ROE	-72.99%
ROE (5Y)	-80.17%
ROIC	-39.95%
SBC / revenue	102.36%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth	-8.13%
Revenue growth (Q)	0.12%
Revenue growth (QoQ)	24.94%
Revenue growth 10Y	40.28%
Revenue growth 3Y	-1.58%
Revenue growth 5Y	10.02%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-16.9M
Depreciation and amortization	$5.5M
EBIT	$-313.9M
EBITDA	$-308.5M
EPS	$-1.41
FCF per share	$-1.16
Financing cash flow	$462.6M
Free cash flow	$-255.1M
Free cash flow minus SBC	$-308.4M
Gross profit	$-178.2M
Investing cash flow	$-16.9M
Net cash flow	$207.5M
Net income	$-301.4M
Operating cash flow minus SBC	$-291.5M
Operating income	$-313.9M
Revenue	$52.1M
Stock-based compensation	$53.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.42
Book value per share	$2.37
Debt / equity	0.15
Interest coverage	-27.53
Long-term assets	$26.9M
Long-term liabilities	$102.1M
Net cash (debt)	$519.3M
Net cash / market cap	33.02%
Net cash growth	65.27%
Net debt / equity	-1
Piotroski F-Score	2
Property, plant and equipment	$25.3M
Shareholders' equity	$520M
Tangible book value	$520M
Tangible book value per share	$2.37
Total assets	$671.3M
Total cash	$598.6M
Total debt	$79.4M
Total liabilities	$151.3M
WACC	9.79%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.09
Current assets	$644.4M
Current liabilities	$49.2M
Current ratio	13.11
Inventory turnover	67.07
Net working capital	$-266,000
Quick ratio	12.79
Working capital	$595.3M
Working capital turnover	0.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-26.4%
Dividend yield	0%
Shareholder yield	-26.4%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	17.65%
10Y return CAGR	1.64%
10Y total return	17.65%
150-day SMA	$9.07
1D price change	7.81%
1M price change	-25.39%
1M total return	-25.39%
1W price change	8.27%
1W total return	8.27%
1Y price change	-37.66%
1Y return CAGR	-37.68%
1Y total return	-37.66%
20-day SMA	$7.02
200-day SMA	$9.15
3M price change	-16.67%
3M total return	-16.67%
3Y price change	197.52%
3Y return CAGR	43.82%
3Y total return	197.52%
50-day SMA	$8.98
50-day SMA vs 200-day SMA	50under200
52-week high	$16.44
52-week high date	2025-12-08
52-week low	$6.00
52-week low date	2026-10-19
5Y price change	6.51%
5Y return CAGR	1.27%
5Y total return	6.51%
6M price change	-24.37%
6M total return	-24.37%
All-time high	$44.19
All-time high date	2015-03-25
All-time low	$2.00
All-time low date	2023-11-10
Average true range (ATR)	$0.49
Average volume	3.3M
Beta (1Y)	1.59
Beta (2Y)	1.49
Beta (5Y)	0.99
Change from 52-week high	-55.93%
Change from 52-week low	20.75%
Change from all-time high	-83.71%
Change from all-time low	260.9%
Change from open	9.44%
Day's gap	-1.49%
Dollar volume	$16.8M
High price	$7.32
Low price	$6.60
Monthly RSI	44.24
Open price	$6.62
Position in 52-week range	89.58%
Premarket change	1.64%
Premarket close	$6.72
Premarket price	$6.83
Premarket volume	1.6K
Previous close	$6.72
Price vs 150-day SMA	-20.6%
Price vs 20-day SMA	2.64%
Price vs 200-day SMA	-21.34%
Price vs 50-day SMA	-19.83%
Relative volume	0.71
RSI	45
Sharpe ratio	-0.32
Sharpe ratio (3Y)	0.82
Sharpe ratio (5Y)	0.23
Sortino ratio	-0.4
Sortino ratio (3Y)	1.4
Sortino ratio (5Y)	0.42
Volume	2.3M
Weekly RSI	41.05
YTD price change	-40.69%
YTD total return	-40.69%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	184.7M
Float percentage	84.1%
Shares change (QoQ)	0.38%
Shares change (YoY)	26.4%
Shares held by insiders	1.23%
Shares held by institutions	80.6%
Shares outstanding	219.6M
Short % of float	15.93%
Short % of shares	13.39%
Short ratio	9.5 days

Deeper analysis on OCUL

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this OCUL report

Is a complete OCUL research report available?

No complete published report is available for Ocular Therapeutix, Inc. (OCUL) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Ocular Therapeutix, Inc. (OCUL)

Price

Financial snapshot

Fair-value bridge

Latest news · OCUL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All OCUL indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on OCUL

Frequently asked questions